182 related articles for article (PubMed ID: 38347143)
1. Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities.
Jiang YZ; Ma D; Jin X; Xiao Y; Yu Y; Shi J; Zhou YF; Fu T; Lin CJ; Dai LJ; Liu CL; Zhao S; Su GH; Hou W; Liu Y; Chen Q; Yang J; Zhang N; Zhang WJ; Liu W; Ge W; Yang WT; You C; Gu Y; Kaklamani V; Bertucci F; Verschraegen C; Daemen A; Shah NM; Wang T; Guo T; Shi L; Perou CM; Zheng Y; Huang W; Shao ZM
Nat Cancer; 2024 Apr; 5(4):673-690. PubMed ID: 38347143
[TBL] [Abstract][Full Text] [Related]
2. Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer.
Dai LJ; Ma D; Xu YZ; Li M; Li YW; Xiao Y; Jin X; Wu SY; Zhao YX; Wang H; Yang WT; Jiang YZ; Shao ZM
Nat Commun; 2023 Aug; 14(1):5112. PubMed ID: 37607916
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
Deng L; Zhu X; Sun Y; Wang J; Zhong X; Li J; Hu M; Zheng H
Cancer Res Treat; 2019 Jan; 51(1):128-140. PubMed ID: 29540052
[TBL] [Abstract][Full Text] [Related]
4. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
Jiang YZ; Ma D; Suo C; Shi J; Xue M; Hu X; Xiao Y; Yu KD; Liu YR; Yu Y; Zheng Y; Li X; Zhang C; Hu P; Zhang J; Hua Q; Zhang J; Hou W; Ren L; Bao D; Li B; Yang J; Yao L; Zuo WJ; Zhao S; Gong Y; Ren YX; Zhao YX; Yang YS; Niu Z; Cao ZG; Stover DG; Verschraegen C; Kaklamani V; Daemen A; Benson JR; Takabe K; Bai F; Li DQ; Wang P; Shi L; Huang W; Shao ZM
Cancer Cell; 2019 Mar; 35(3):428-440.e5. PubMed ID: 30853353
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
[TBL] [Abstract][Full Text] [Related]
6. Clustering of HR + /HER2- breast cancer in an Asian cohort is driven by immune phenotypes.
Pan JW; Ragu M; Chan WQ; Hasan SN; Islam T; Teoh LY; Jamaris S; See MH; Yip CH; Rajadurai P; Looi LM; Taib NAM; Rueda OM; Caldas C; Chin SF; Lim J; Teo SH
Breast Cancer Res; 2024 Apr; 26(1):67. PubMed ID: 38649964
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
Li G; Guo X; Chen M; Tang L; Jiang H; Day JX; Xie Y; Peng L; Xu X; Li J; Wang S; Xiao Z; Dai L; Wang J
PLoS One; 2018; 13(9):e0203495. PubMed ID: 30212483
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
[TBL] [Abstract][Full Text] [Related]
9. Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers.
Shimoi T; Hashimoto J; Sudo K; Shimomura A; Noguchi E; Shimizu C; Yunokawa M; Yonemori K; Yoshida H; Yoshida M; Kato T; Kinoshita T; Fukuda T; Fujiwara Y; Tamura K
BMC Cancer; 2021 Oct; 21(1):1131. PubMed ID: 34670536
[TBL] [Abstract][Full Text] [Related]
10. Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer.
Verschoor N; Smid M; Jager A; Sleijfer S; Wilting SM; Martens JWM
Breast Cancer Res; 2023 Nov; 25(1):145. PubMed ID: 37968696
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients.
Tong L; Yang XX; Liu MF; Yao GY; Dong JY; Ye CS; Li M
Asian Pac J Cancer Prev; 2012; 13(11):5599-603. PubMed ID: 23317280
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Turner NC; Kingston B; Kilburn LS; Kernaghan S; Wardley AM; Macpherson IR; Baird RD; Roylance R; Stephens P; Oikonomidou O; Braybrooke JP; Tuthill M; Abraham J; Winter MC; Bye H; Hubank M; Gevensleben H; Cutts R; Snowdon C; Rea D; Cameron D; Shaaban A; Randle K; Martin S; Wilkinson K; Moretti L; Bliss JM; Ring A
Lancet Oncol; 2020 Oct; 21(10):1296-1308. PubMed ID: 32919527
[TBL] [Abstract][Full Text] [Related]
13. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
[TBL] [Abstract][Full Text] [Related]
15. Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
Li K; Liao N; Chen B; Zhang G; Wang Y; Guo L; Wei G; Jia M; Wen L; Ren C; Cao L; Mok H; Li C; Lin J; Chen X; Zhang Z; Hou T; Li M; Liu J; Balch CM; Liao N
Breast Cancer Res Treat; 2020 Sep; 183(2):321-332. PubMed ID: 32638235
[TBL] [Abstract][Full Text] [Related]
16. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
[TBL] [Abstract][Full Text] [Related]
17. Genetic landscape of breast cancer and mutation tracking with circulating tumor DNA in Chinese women.
Wang Y; Lin L; Li L; Wen J; Chi Y; Hao R; Dai X; Chen Y; Huang D; Zhou Y; You J; Ye Z; Chen H; Jin L; Chen D; Yang F; Xia E; Ma X; Guo F; Tong Y; Zheng M; Wang O
Aging (Albany NY); 2021 Apr; 13(8):11860-11876. PubMed ID: 33893247
[TBL] [Abstract][Full Text] [Related]
18. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
19. Molecular portrait of breast cancer in China reveals comprehensive transcriptomic likeness to Caucasian breast cancer and low prevalence of luminal A subtype.
Huang X; Dugo M; Callari M; Sandri M; De Cecco L; Valeri B; Carcangiu ML; Xue J; Bi R; Veneroni S; Daidone MG; Ménard S; Tagliabue E; Shao Z; Wu J; Orlandi R
Cancer Med; 2015 Jul; 4(7):1016-30. PubMed ID: 25787708
[TBL] [Abstract][Full Text] [Related]
20. Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets.
Su GH; Xiao Y; You C; Zheng RC; Zhao S; Sun SY; Zhou JY; Lin LY; Wang H; Shao ZM; Gu YJ; Jiang YZ
Sci Adv; 2023 Oct; 9(40):eadf0837. PubMed ID: 37801493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
